RecruitMe Clinical Trial

ADVL1414, A Phase 1 Study of Selinexor (KPT-330), a Selective XP01 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Study of Selinexor in Pediatric Solid Tumors, including CNS Tumors
Sponsor:Children's Oncology Group
Enrolling:Male and Female Patients
Age Range:Between 1 and 21 years old
IRB Number:AAAQ4204
U.S. Government ID:NCT02323880
Contact: Alice Lee, MD: 212-305-7212 / al2041@cumc.columbia.edu
Additional Study Information:

We are testing new experimental drugs such as selinexor in the hopes of finding a treatment that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this study are: To find the highest safe dose of selinexor that can be given without causing severe side effects; To learn what kind of side effects selinexor can cause; To learn more about the pharmacology (how your body handles the drug) of selinexor; To learn more about the biology of selinexor in blood and tumor tissue; To determine whether selinexor is a beneficial treatment for your tumor.

Do You Qualify?
Does your child have a solid tumor, including lymphoma and CNS tumors, or a glioma?YesNo
Is your child between 12 months to 21 years of age?YesNo
Has your child received a solid organ transplantation?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Alice Lee, MD
Email: al2041@cumc.columbia.edu
Phone: 212-305-7212